Bristol Myers' Myeloma Win Is the First Hard Proof Its Post-Revlimid Pipeline Works

At this year's ASCO cancer meeting, Bristol Myers Squibb (BMY) answered the question that has hung over the stock for years: whether its next-generation pipeline can actually deliver after its largest patented revenue fades. The data were unambiguous. Mezigdomide — an oral drug from the CELMoD platform, the targeted-protein-degradation technology BMS has treated as the centerpiece of its post-Revlimid future — cut the risk of disease progression or death by 52% versus standard care in relapsed or refractory multiple myeloma. In a name the market had largely written off as a promise, that single readout was the proof the bull case had been missing.

The trial that ended the doubt

The reason this one result matters more than a routine drug headline is what BMS's old story became. For years the company's narrative was a countdown: Revlimid, the backbone of its once-huge blood-cancer franchise, was losing patent protection, and the market treated Bristol Myers as a slow, dividend-paying value trap with a pipeline that talked more than it showed. Everything rides on whether newer medicines can fill that hole. Mezigdomide is that thesis given a number, not in an easy cancer, but in the hardest one there is.

The SUCCESSOR-2 trial enrolled patients whose disease had already returned after prior therapy — the most difficult end of the multiple-myeloma spectrum. More than 92% of them were triple-class exposed, and most had become refractory to both anti-CD38 antibodies and lenalidomide, meaning the current standard tools had stopped working. In that population, adding mezigdomide to a standard carfilzomib-and-dexamethasone regimen stretched median time-to-progression from 8.3 months to 18 months, and lifted the overall response rate from about 53% to 80%. This was the first Phase 3 confirmation that the entire CELMoD platform — not a single flattering study — produces real clinical effect where existing medicines fail.

Because it is early, that confidence has a boundary. The regulatory clock is now concrete: the FDA accepted the new drug application for relapsed or refractory multiple myeloma, with a decision date of May 13, 2027 — a defined catalyst inside the next twelve months, not a distant hope. A second Phase 3 trial, SUCCESSOR-1, is still reading out.

The money backs it up

A pipeline win alone is not an investment thesis, so I follow the trial with the cash-flow question. The operating picture is improving in step. When it reported second-quarter results in late July, Bristol Myers raised its full-year outlook: it now guides 2026 revenue to roughly $49 billion to $50 billion, up from the prior $46 billion to $47.5 billion, and non-GAAP earnings of $6.75 to $7.00 per share, up from $6.05 to $6.35. The driver is the "growth portfolio" of newer medicines built to replace the legacy — it grew 15% in the quarter to about $7.6 billion, led by Opdivo Qvantig, Breyanzi, Reblozyl and Camzyos, while Eliquis got a guidance boost of its own. The old fear, in other words, is being offset by the new reality.

That is where the valuation does its work. Even after the stock has climbed roughly 17% this year and more than a third over the trailing twelve months, Bristol Myers trades near $63 with about $11.4 billion in trailing free cash flow on a market capitalization around $129 billion — a cash-flow multiple close to 11 times, sitting under a ~3.9% dividend that has been raised for three consecutive years. Put differently, the market is still pricing meaningful parts of the old risk profile — a fading Revlimid, skepticism about the pipeline — while the operating setup looks cleaner than the sentiment. The aggregate analyst signal still labels the stock a Hold, even as its fundamental ratings are strong, which is roughly the shape you want to see as the story turns from denial to acceptance.

The honest risk

None of this softens the strongest bear case, and it deserves to be stated plainly. Multiple myeloma is a relentlessly competitive field dominated by entrenched standard-of-care franchise owners, and mezigdomide's safety data carry a real cost: grade 3-4 side effects ran far higher with the drug (about 84% versus 56% in the control arm), driven largely by a class of low blood counts that raises infection risk. Overall survival data are not yet mature — survival is the statistic that will ultimately decide how the drug is positioned and priced. If the toxicity caps real-world uptake, or if survival fails to follow the progression benefit, the commercial ceiling is lower than today's enthusiasm assumes.

That is also the concrete condition the bull case depends on. The free cash flow that supports the ~11 times multiple declined year over year, so the rerating rests on that figure recovering as restructuring and the portfolio shift settle out. What must happen for the story to stay intact: the legacy decline keeps being offset, mezigdomide converts its progression win into approval and adoption — and survival data confirm the benefit rather than contradict it. Watch the PDUFA date and the SUCCESSOR readouts as the proof points. If the cash flow keeps sliding and the pipeline fails to convert, the cheapness was real for a reason. If the inflection holds, Bristol Myers is a case where the next twelve months improve before the broader market fully trusts it.